Advertisement

Clinical and Experimental Medicine

, Volume 17, Issue 3, pp 333–340 | Cite as

Long-term safety of umbilical cord mesenchymal stem cells transplantation for systemic lupus erythematosus: a 6-year follow-up study

  • Dandan Wang
  • Lingying Niu
  • Xuebing Feng
  • Xinran Yuan
  • Shengnan Zhao
  • Huayong Zhang
  • Jun Liang
  • Cheng Zhao
  • Hong Wang
  • Bingzhu Hua
  • Lingyun SunEmail author
Original Article

Abstract

The aim of this study is to assess the long-term safety of allogeneic umbilical cord mesenchymal stem cells (UC MSCs) transplantation for patients with refractory systemic lupus erythematosus (SLE). Nine SLE patients, who were refractory to steroid and immunosuppressive drugs treatment and underwent MSCs transplantation in 2009, were enrolled. One million allogeneic UC MSCs per kilogram of body weight were infused intravenously at days 0 and 7. The possible adverse events, including immediately after MSCs infusions, as well as the long-term safety profiles were observed. Blood and urine routine test, liver function, electrocardiogram, chest radiography and serum levels of tumor markers, including alpha fetal protein (AFP), cancer embryo antigen (CEA), carbohydrate antigen 155 (CA155) and CA199, were assayed before and 1, 2, 4 and 6 years after MSCs transplantation. All the patients completed two times of MSCs infusions. One patient had mild dizzy and warm sensation 5 min after MSCs infusion, and the symptoms disappeared quickly. No other adverse event, including fluster, headache, nausea or vomit, was observed. There was no change in peripheral white blood cell count, red blood cell count and platelet number in these patients after followed up for 6 years. Liver functional analysis showed that serum alanine aminotransferase, glutamic-oxalacetic transaminase, total bilirubin and direct bilirubin remained in normal range after MSCs infusions. No newly onset abnormality was detected on electrocardiogram and chest radiography. Moreover, we found no rise of serum tumor markers, including AFP, CEA, CA125 and CA199, before and 6 years after MSCs infusions. Our long-term observational study demonstrated a good safety profile of allogeneic UC MSCs in SLE patients.

Keywords

Mesenchymal stem cells Umbilical cord Systemic lupus erythematosus Safety 

Notes

Acknowledgments

The study was supported by the Major International (Regional) Joint Research Project (81120108021), National Natural Science Foundation of China (81273304, 81401347, 81302558, 81202333, 81401353), Jiangsu Provincial Natural Science Foundation (BK20140098), Jiangsu Provincial Health Department Foundation (Q201411) and the Scientific Research Project of Nanjing Municipal Health Bureau (YKK14067).

Compliance with ethical standards

Conflict of interest

The authors declare no conflict of interest.

References

  1. 1.
    U.S. National Institutes of Health. Search for clinical trials involving “mesenchymal stem cells”. US National Institutes of Health. pp search terms: mesenchymal stem cells.Google Scholar
  2. 2.
    Orozco L, Soler R, Morera C, et al. Intervertebral disc repair by autologous mesenchymal bone marrow cells: a pilot study. Transplantation. 2011;92(7):822–8.CrossRefPubMedGoogle Scholar
  3. 3.
    Li X, Liu L, Meng D, et al. Enhanced apoptosis and senescence of bone-marrow-derived mesenchymal stem cells in patients with systemic lupus erythematosus. Stem Cells Dev. 2012;21:2387–94.CrossRefPubMedGoogle Scholar
  4. 4.
    Sun L, Wang D, Liang J, et al. Umbilical cord mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus. Arthritis Rheum. 2010;62:2467–75.CrossRefPubMedGoogle Scholar
  5. 5.
    Liang J, Zhang H, Hua B, et al. Allogenic mesenchymal stem cells transplantation in refractory systemic lupus erythematosus: a pilot clinical study. Ann Rheum Dis. 2010;69:1423–9.CrossRefPubMedGoogle Scholar
  6. 6.
    Wang Y, Han ZB, Ma J, et al. A toxicity study of multiple-administration human umbilical cord mesenchymal stem cells in cynomolgus monkeys. Stem Cells Dev. 2012;21:1401–8.CrossRefPubMedGoogle Scholar
  7. 7.
    Ra JC, Shin IS, Kim SH, et al. Safety of intravenous infusion of human adipose tissue-derived mesenchymal stem cells in animals and humans. Stem Cells Dev. 2011;20:1297–308.CrossRefPubMedGoogle Scholar
  8. 8.
    Zhou KX, Zhang HY, Jin OY, et al. Transplantation of human bone marrow mesenchymal stem cell ameliorates the autoimmune pathogenesis in MRL/lpr mice. Cell Mol Immunol. 2008;5:417–24.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Gu Z, Akiyama K, Ma X, et al. Transplantation of umbilical cord mesenchymal stem cells alleviates lupus nephritis in MRL/lpr mice. Lupus. 2010;19:1502–14.CrossRefPubMedGoogle Scholar
  10. 10.
    Wang D, Huang S, Yuan X, et al. The regulation of the Treg/Th17 balance by mesenchymal stem cells in human systemic lupus erythematosus. Cell Mol Immunol. 2015;. doi: 10.1038/cmi.2015.89.Google Scholar
  11. 11.
    Sun L, Akiyama K, Zhang H, et al. Mesenchymal stem cell transplantation reverses multiorgan dysfunction in systemic lupus erythematosus mice and humans. Stem Cells. 2009;27(6):1421–32.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Che N, Li X, Zhang L, et al. Impaired B cell inhibition by lupus bone marrow mesenchymal stem cells is caused by reduced CCL2 expression. J Immunol. 2014;193(10):5306–14.CrossRefPubMedGoogle Scholar
  13. 13.
    Liu S, Liu D, Chen C, et al. MSC transplantation improves osteopenia via epigenetic regulation of Notch signaling in lupus. Cell Metab. 2015;22(4):606–18.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Smith EL, Shmerling RH. The American College of Rheumatology criteria for the classification of systemic lupus erythematosus: strengths, weaknesses, and opportunities for improvement. Lupus. 1999;8:586–95.CrossRefPubMedGoogle Scholar
  15. 15.
    Wang D, Zhang H, Liang J, et al. Allogeneic mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus: 4 years experience. Cell Transplant. 2013;22:2267–77.CrossRefPubMedGoogle Scholar
  16. 16.
    Wang D, Li J, Zhang Y, et al. Umbilical cord mesenchymal stem cell transplantation in active and refractory systemic lupus erythematosus: a multicenter clinical study. Arthritis Res Ther. 2014;16:R79.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Le Blanc K, Frassoni F, Ball L, et al. Developmental committee of the European group for blood and marrow transplantation: mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet. 2008;371:1579–86.CrossRefPubMedGoogle Scholar
  18. 18.
    Ball LM, Bernardo ME, Roelofs H, et al. Co-transplantation of ex vivo expanded mesenchymal stem cells accelerates lymphocyte recovery and may reduce the risk of graft failure in haploidentical hematopoietic stem cell transplantation. Blood. 2007;110:2764–7.CrossRefPubMedGoogle Scholar
  19. 19.
    Hare JM, Fishman JE, Gerstenblith G, et al. Comparison of allogeneic versus autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial. JAMA. 2012;308:2369–79.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Song H, Song BW, Cha MJ, et al. Modification of mesenchymal stem cells for cardiac regeneration. Expert Opin Biol Ther. 2010;10:309–19.CrossRefPubMedGoogle Scholar
  21. 21.
    Akiyama K, Chen C, Wang D, et al. Mesenchymal stem cell-induced immunoregulation involves Fas Ligand/Fas-mediated T cell apoptosis. Cell Stem Cell. 2012;10:544–55.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Liang J, Zhang H, Wang D, et al. Allogeneic mesenchymal stem cells transplantation in seven patients with refractory inflammatory bowel disease. Gut. 2012;61:468–9.CrossRefPubMedGoogle Scholar
  23. 23.
    Ciccocioppo R, Bernardo ME, Sgarella A, et al. Autologous bone marrow-derived mesenchymal stromal cells in the treatment of fistulising Crohn’s disease. Gut. 2011;60:788–98.CrossRefPubMedGoogle Scholar
  24. 24.
    Wang D, Zhang H, Cao M, et al. Efficacy of allogeneic mesenchymal stem cell transplantation in patients with drug-resistant polymyositis and dermatomyositis. Ann Rheum Dis. 2011;70:1285–8.CrossRefPubMedGoogle Scholar
  25. 25.
    Liang J, Li X, Zhang H, et al. Allogeneic mesenchymal stem cells transplantation in patients with refractory RA. Clin Rheumatol. 2012;31:157–61.CrossRefPubMedGoogle Scholar
  26. 26.
    Xu J, Wang D, Liu D, et al. Allogeneic mesenchymal stem cell treatment alleviates experimental and clinical Sjogren syndrome. Blood. 2012;120:3142–51.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Ezquer FE, Ezquer ME, Parrau DB, et al. Systemic administration of multipotent mesenchymal stromal cells revert hyperglycaemia and prevents nephropathy in type 1 diabetic mice. Biol Blood Marrow Transplant. 2008;14:631–40.CrossRefPubMedGoogle Scholar
  28. 28.
    Jiang R, Han Z, Zhuo G, et al. Transplantation of placenta-derived mesenchymal stem cells in type 2 diabetes: a pilot study. Front Med. 2011;5:94–100.CrossRefPubMedGoogle Scholar
  29. 29.
    Kniazev OV, Parfenov AI, Konopliannikov AG, et al. Safety of mesenchymal stromal cell therapy for inflammatory bowel diseases: results of a 5-year follow-up. Ter Arkh. 2015;87:39–44.CrossRefGoogle Scholar
  30. 30.
    Lee PH, Lee JE, Kim HS, et al. A randomized trial of mesenchymal stem cells in multiple system atrophy. Ann Neurol. 2012;72:32–40.CrossRefPubMedGoogle Scholar
  31. 31.
    Tarte K, Gaillard J, Lataillade JJ, et al. Clinical-grade production of human mesenchymal stromal cells: occurrence of aneuploidy without transformation. Blood. 2010;115:1549–53.CrossRefPubMedGoogle Scholar
  32. 32.
    Bank JR, Rabelink TJ, de Fijter JW, et al. Safety and efficacy endpoints for mesenchymal stromal cell therapy in renal transplant recipients. J Immunol Res. 2015;2015:391797.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Yang K, Wang J, Wu M, et al. Mesenchymal stem cells detect and defend against gamma herpesvirus infection via the cGAS-STING pathway. Sci Rep. 2015;5:7820.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Mao YX, Xu JF, Seeley EJ, et al. Adipose tissue-derived mesenchymal stem cells attenuate pulmonary infection caused by pseudomonas aeruginosa via inhibiting overproduction of prostaglandin E2. Stem Cells. 2015;33:2331–42.CrossRefPubMedGoogle Scholar
  35. 35.
    Xie C, Zheng YB, Zhu HP, et al. Human bone marrow mesenchymal stem cells are resistant to HBV infection during differentiation into hepatocytes in vivo and in vitro. Cell Biol Int. 2009;33:493–500.CrossRefPubMedGoogle Scholar
  36. 36.
    Sasser AK, Mundy BL, Smith KM, et al. Human bone marrow stromal cells enhance breast cancer cell growth rates in a cell line-dependent manner when evaluated in 3D tumor environments. Cancer Lett. 2007;254:255–64.CrossRefPubMedGoogle Scholar
  37. 37.
    Zhu W, Xu W, Jiang R, et al. Mesenchymal stem cells derived from bone marrow favor tumor cell growth in vivo. Exp Mol Pathol. 2006;80:267–74.CrossRefPubMedGoogle Scholar
  38. 38.
    Arango-Rodriguez ML, Ezquer F, Ezquer M, Conget P. Could cancer and infection be adverse effects of mesenchymal stromal cell therapy? World J Stem Cells. 2015;7:408–17.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Lalu MM, McIntyre L, Pugliese C, et al. Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials. PLoS One. 2012;7:e47559.CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Ramdasi S, Sarang S, Viswanathan C. Potential of mesenchymal stem cell based application in cancer. Int J Hematol Oncol Stem Cell Res. 2015;9:95–103.PubMedPubMedCentralGoogle Scholar
  41. 41.
    Baydar DE, Himmetoglu C, Yazici S, et al. Primary osteosarcoma of the urinary bladder following cyclophosphamide therapy for systemic lupus erythematosus: a case report. J Med Case Rep. 2009;3:39.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  • Dandan Wang
    • 1
  • Lingying Niu
    • 1
  • Xuebing Feng
    • 1
  • Xinran Yuan
    • 1
  • Shengnan Zhao
    • 1
  • Huayong Zhang
    • 1
  • Jun Liang
    • 1
  • Cheng Zhao
    • 1
  • Hong Wang
    • 1
  • Bingzhu Hua
    • 1
  • Lingyun Sun
    • 1
    Email author
  1. 1.Department of Rheumatology and ImmunologyThe Affiliated Drum Tower Hospital of Nanjing University Medical SchoolNanjingChina

Personalised recommendations